Tumors with germline or acquired somatic alterations in the main mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) accumulate genomic alterations and dMMR is a proxy for elevated tumor mutational burden and presumably neoantigen load [33]. This evidence concerns the gene MSH2 and neoplasm.